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Abstract:
Background: Remission in schizophrenia is difficult to achieve. Antipsychotic drugs are critical in the treatment of schizophrenia. International
guidelines for the pharmacological treatment of schizophrenia recommend
a 3-step algorithm with clozapine being the third-line antipsychotic agent.
This study investigated the 1-year outcome and the application of the
guidelines for the pharmacological treatment of nonremitted first-episode
schizophrenia (FES) patients during the first year of follow-up.
Methods: A sample of 78 FES patients from the Norwegian TIPS (Early
Treatment and Intervention in Psychosis) 2 study was assessed at the end of
the first year of follow-up. The symptom remission criteria were those defined by the Remission in Schizophrenia Working Group. The adherence
to the pharmacological guidelines was assessed by reading the medical files
and by a digital search of the words “clozapine,” “klozapin,” and “Leponex”
in the hospital electronic data system.
Results: The majority (n = 53, 67.9%) of the patients included were
nonremitted at the 1-year follow-up. The majority of the nonremitted patients received either none (7.5%), one (56.6%), or 2 types (15.1%) of antipsychotic drugs during the first year of follow-up. Only 2 (3.8%) received
treatment with clozapine, and 3 (5.7%) in total were offered it.
Conclusions: For our FES sample, there was a low 1-year remission rate
and a poor adherence to the pharmacological guidelines. Higher adherence
to treatment guidelines with a more intensified antipsychotic treatment,
which in some cases will include clozapine, will enhance the quality of
treatment and may enhance the rates of remission for schizophrenia.
Key Words: schizophrenia, first episode, remission, guidelines,
antipsychotics
(J Clin Psychopharmacol 2020;40: 534–540)

S

chizophrenia is a severe mental illness with serious consequences for the majority of patients and their families, and
for society at large, even though many patients have a favorable
course.1–3 Despite the establishment of early detection and
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intervention services and the development of new psychosocial
interventions, 40% to 50% of patients with first-episode schizophrenia (FES) have symptoms at 10 years of follow-up.4,5 Studies
examining the 1-year outcome in FES, show highly variable remission rates ranging from 17% to 81%.6,7
Antipsychotic medication remains the most effective treatment for positive symptoms in schizophrenia.8 Clozapine has
been shown to be the most efficacious drug in this drug class.9
Moreover, clozapine is effective in about one third of patients
not responding to 2 trials with nonclozapine antipsychotics, hereafter termed the treatment-resistant patients.10 The antipsychotic
treatment algorithms incorporated in the guidelines for the treatment of schizophrenia are outlined in Figure 1.11–16 The algorithms
generally recommend 2 trials with different antipsychotic drugs of
adequate dosing and duration before clozapine is indicated. However, the initiation of clozapine may not match the time frame given
in guidelines. The profile of adverse effects for clozapine may increase this delay in the treatment of FES patients, who are generally
more vulnerable to antipsychotic adverse effects such as weight
gain and the metabolic syndrome.17 However, clozapine has
achieved favorable results in the treatment of FES patients. One
study examined the use of clozapine in a cohort of consecutive
FES patients with a 2-year follow-up.18 Although patients who received clozapine had more positive and negative symptoms at baseline, they managed to reach rates of remission and recovery similar
to those who had never received clozapine, indicating additional effects of clozapine for FES. Another study showed a robust response
to clozapine for FES patients who had not responded well to initial
trials of second-generation antipsychotic drugs.19 The use of clozapine as a second-line antipsychotic for FES-spectrum disorders has
also achieved favorable results.20
Given the serious long-term sequences of nonremission in
FES,21 optimization of the antipsychotic treatment with thorough
consideration of clozapine and skillful long-term specialist
follow-up are of outmost importance in this patient group.
We aimed to study the 1-year remission rate and the antipsychotic treatment for a cohort of consecutively recruited FES patients. The prescribed antipsychotic treatment was compared
with treatment guideline recommendations.

METHODS
The sample is drawn from the TIPS (Early Treatment and
Intervention in Psychosis) 2 cohort study that included all
first-episode psychosis patients admitted to either outpatient
clinics or hospital.22–25 The study was carried out within the publicly funded specialist psychiatric catchment area services in
Rogaland County, Norway, with a total of 370,000 inhabitants.
The study comprises data from the time of inclusion until 1-year
follow-up. All patients were assessed within a week of contact
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to August 2013. The inclusion criteria were the following: living
in the catchment area in Rogaland County, Norway; age 15 to
65 years; meeting the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) (DSM-IV; American Psychiatric
Association, 1994) criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder, described further on as core
schizophrenia; being actively psychotic, as measured by the Positive
and Negative Syndrome Scale (PANSS)26 score of 4 or more on at
least 1 of the Positive subscale items: 1 (delusions), 3 (hallucinatory
behavior), 5 (grandiosity), 6 (suspiciousness/persecution), or General
subscale item 9 (unusual thought content); not receiving previous adequate treatment for psychosis (defined as antipsychotic medication
of more than 3.5 haloperidol equivalents for 12 weeks or until remission of the psychotic symptoms); having no neurological or endocrine
disorders with relationship to the psychosis; having no contraindications to antipsychotic medication; understanding and/or speaking a
Scandinavian language; having an IQ score of higher than 70.
From the total cohort, 122 had a core-schizophrenia diagnosis (FES). From this group of 122 FES patients, 78 completed the
1-year follow-up, as shown in Figure 2.

Design

FIGURE 1. The algorithm for the pharmacological treatment of FES.

with the psychiatric services and assigned to the standard treatment
program consisting of an antipsychotic medication algorithm, multifamily group work, and supportive psychotherapy. All patients entering the study gave written informed consent. The project
received ethical approval from the Regional Committee for Medical
Research Ethics Health Region West, Norway (015.03).

Participants
This study included all eligible participants with FES recruited to the TIPS cohort study during the period January 2002

The study was an observational cohort design with a 1-year
follow-up. Participants were categorized as remitted or nonremitted
according to their remission status, as per the Remission in Schizophrenia Working Group criteria27 (see hereinafer), at the 1-year
follow-up. Participant characteristics at baseline and 1-year followup were compared, and the pharmacological treatment was assessed
in detail. The algorithm used in TIPS was recommended as a standard hospital policy and was a modification of the Norwegian treatment guidelines.15

Assessments
For the TIPS cohort, patients were assessed at baseline,
3 months, and 12 months. For this study, only the baseline and
12 month assessments were used. Assessment teams were clinically experienced and trained research personnel. Raters were
trained by rating preprepared case notes and audio/videotapes.
Good interrater reliability was achieved on major parameters in

FIGURE 2. Flow chart with studied population. Remission was defined in accordance with the Remission in Schizophrenia Working Group
standardized symptom remission criteria.27
© 2020 The Author(s). Published by Wolters Kluwer Health, Inc.
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the research group.25 The Structured Clinical Interview for
DSM-IV Axis I disorders was used for diagnostic purposes.28
Symptom levels were measured by the PANSS.26 For the PANSS,
we calculated the total and the positive, negative, excitative, depressive, and cognitive component scores. Other characteristics
were also assessed, such as suicidality and duration of untreated
psychosis (DUP). Presence of suicidality was defined as having
suicidal thoughts, plans, or attempts. The DUP was measured as
the time from onset of psychosis until the start of adequate treatment. Onset of psychosis was defined as the first week with positive
psychotic symptoms corresponding to a PANSS score of 4 or more
on Positive subscale items 1, 3, 5, or 6 or on General subscale item
9. In cases with long DUP, all available data sources were used to
ascertain the length of this period to the best achievable level, including semistructured personal interviews with patients and relatives. Adequate treatment was defined as the start of structured
treatment with antipsychotic medication, start of hospitalization,
or the start of outpatient clinic psychotherapy designed to manage
psychotic symptoms.25 Global functioning was measured by the
Global Assessment of Functioning scale with scores calculated
for symptom and function subscales.29 Misuse or dependence of alcohol and drugs was measured by the Clinicians Rating Scale.30

Remission
Remission was defined in accordance with the Remission in
Schizophrenia Working Group standardized symptom remission
criteria.27 The Remission in Schizophrenia Working Group is a
panel of experts from the United States, who developed in 2004
a consensus definition of remission applied to schizophrenia.
The proposed criteria were also supported by international field
experts and were published in 2005. These criteria consist of no

score of 4 or higher for the past 6 months on any of the following
PANSS items: P1 (delusions), P2 (disorganized thought), P3 (hallucinatory behavior), N1 (affective flattening), N4 (passive social
withdrawal), N6 (lack of spontaneity), G5 (bizarre posture), or G9
(unusual thought content). Patients were categorized as nonremitted
if they reported any relapse, defined as deterioration of symptoms
with score of >4 on the relevant PANSS subscales during the previous 6 months. Remission status at the last available observation was
based on the assessment at the 1-year follow-up.

Pharmacological Treatment
At 1-year follow-up, we examined the pharmacological strategies applied for patients by assessing adherence to the algorithm
using patient files. The algorithm described 3 drug alternatives
with clozapine being the third drug of choice, as shown in Figure 1.
The first author (P.D.) read all the patient files and clinical descriptions (Structured Clinical Interview for DSM-IV and PANSS) to
ascertain whether participants had remitted or relapsed during
the first year of follow-up. Clinical descriptions were scrutinized
and assessed for indications for a switch to clozapine. Pharmacological treatment was assessed in detail. The total duration of antipsychotic treatment, as well as the number of periods with
antipsychotic treatment, was calculated using the patient files.
The different antipsychotics used as first, second, third, or fourth
choice were also assessed. In addition, the first author performed
a digital search in all the medical files of the patients in the hospital
data system, with index “clozapine,” “klozapin” (the Norwegian
term for clozapine), and “Leponex” (the brand name for clozapine
in Norway). Unclear cases were discussed with one of the coauthors
(T.K.L.). Whenever possible, we sought to identify the reasons for
clozapine not being considered or offered to patients.

TABLE 1. Characteristics of 78 Patients With First-Episode Core Schizophrenia, Divided by Remission Status at 1-Year Follow-up
Baseline
Remitted (n = 25) (32%)
Male, n (%)
Age, mean (SD)
Years of education, mean (SD)
GAF, symptom, mean (SD)
GAF, function, mean (SD)
PANSS, mean (SD)
Positive
Negative
Excitative
Depressive
Cognitive
Suicidality, n (%)
DUP
Median (SD), wk
Interquartile range
Alcohol misuse/dependence, n (%)
Drugs misuse/dependence, n (%)

16 (64)
27.4 (9.6)
12.6 (4.1)
31.5 (7.7)
41.2 (9.3)

1y

Nonremitted (n = 53) (68%)
38 (72)
26.1 (7.6)
12 (2.1)
30.8 (6.3)
38.7 (9.5)

3.3 (0.72)
2.1 (0.86)
1.5 (0.54)
3.2 (1.05)
1.8 (0.85)
16 (66.6)

3.3 (0.9)
2.4 (1.15)
1.6 (0.78)
3 (1.18)
2.3 (1.27)
34 (65.4)

16 (176.2)
41.5
2 (8.3)
3 (12.5)

40 (304)*
144
9 (17)
15 (28.3)

P

Nonremitted (n = 53)

36.3 (8.5)*
41.7 (10.3)*

0.492
0.776
0.089
0.410
0.211

2.7 (0.89)
2.3 (0.84)
1.3 (0.65)
2.5 (1.2)
1.8 (1)
16 (39)†

0.759
0.259
0.822
0.461
0.188
0.999
0.054

7 (14.3)‡
14 (28.6)‡

0.486
0.156

All P values are based on baseline comparisons.
*n = 51.
†
n = 41.
‡
n = 49.
GAF indicates Global Assessment of Functioning scale.
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Data Analysis
Analyses were performed using the SPSS Statistical Program
Package version 20.0 (IBM, Armonk, NY). Participants were
classified according to remission status (yes/no) at the 1-year
follow-up. Categorical variables were presented in cross tables
and analyzed using χ2 or Fisher exact test as appropriate. All
group comparisons of continuous and ordinal data were analyzed
using the nonparametric Mann-Whitney U test because of nonnormality as assessed with visual inspection of histograms.

RESULTS
Sample Characteristics and 1-Year Remission
Characteristics of the remitted and nonremitted groups are
outlined in Table 1. A total of 78 patients were included in the
sample, and the majority (68%) were nonremitted at the 1-year
follow-up. All of the nonremitted patients (n = 53) scored 4 or
more on at least 1 of the positive symptoms included in the remission criteria, whereas this was the case for 43 patients (81% of the
nonremitted) regarding the negative and general symptoms. Both
groups comprised mostly young men (mean age of 27 and
26 years, respectively, for the remitted and nonremitted group;
64% and 72%, respectively, were men).
At baseline, there were no significant differences between the
remitted and nonremitted group for sex, age, years of education,
symptom, and function profile (Global Assessment of Functioning scale, PANSS), misuse or dependence of alcohol and drugs,
and suicidality. We found a trend for DUP being longer in the
nonremitted group, but this was not statistically significant (median of 40 weeks compared with 16 weeks, P = 0.054).

Antipsychotic Treatment in the Remitted and the
Nonremitted Groups
The average number of periods of treatment with any antipsychotic drugs and the total duration of treatment during the first
year were not significantly different between the 2 groups, as
shown in Table 2.
Two patients (8%) in the remitted group and 4 patients (7%)
in the nonremitted group had no trials of antipsychotic drugs during
the study period. The majority in both groups, 17 patients (68%) of
the remitted and 30 patients (57%) of the nonremitted, received 1
type of antipsychotic drug during the first year. Four remitted patients (16%) and 8 nonremitted patients (15%) were treated with 2
different antipsychotic drugs. There were no significant group differences for no use of antipsychotic drugs, use of 1 antipsychotic
drug, or use of 2 or more antipsychotic drugs.
Regarding the first-choice antipsychotic drug, there were no
significant group differences. The most frequently prescribed antipsychotic drugs were olanzapine, risperidone, and quetiapine.
Olanzapine was the first used antipsychotic drug for 48% of the
remitted patients and 45% of the nonremitted (remitted, 11;
nonremitted, 22 patients).
Three (6%) of the nonremitted patients were offered, and 2
(4%) received treatment with clozapine. For 1 patient, this was a
second-choice drug, and for the other one, this was a fourth choice.
There was no information that indicated an evaluation of clozapine
for any of the other patients in the sample.
The vast majority of patients were treated with second-generation
antipsychotic drugs. None of the remitted patients was treated
with first-generation antipsychotic drugs. Of the nonremitted patients, 8% were treated with a first-generation antipsychotic as a
first-choice drug. Three of the 4 patients were switched to
second-generation antipsychotic drugs only. The fourth patient
© 2020 The Author(s). Published by Wolters Kluwer Health, Inc.
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was switched first to olanzapine and then to levomepromazine,
which is a first-generation antipsychotic drug. Two more patients
were treated with a first-generation antipsychotic as a second-choice
drug. The first one switched from risperidone to haloperidol and
had no further switches during the first year. The second patient
switched from olanzapine to haloperidol, then switched from haloperidol to perphenazine (another first-generation antipsychotic
drug), and finally from perphenazine to risperidone.

TABLE 2. Use of Medication During First Year of Treatment for
Patients With First-Episode Core Schizophrenia, Divided by
Remission Status at 1-Year Follow-up
Remitted Nonremitted
(n = 25)
(n = 53)
Total duration of antipsychotic
treatment, mean (SD), wk
No. periods with antipsychotic
treatment, n (SD)

P

n = 22
n = 51
0.196
41.5 (15.7) 33.9 (20.2)
n = 25
n = 53
0.481
1.32 (0.8) 1.5 (1.05)
n = 25
n = 53
17 (68)
30 (56.6)
4 (16)
8 (15.1)
2 (8)
9 (17)
0 (0)
2 (3.8)
2 (8)
4 (7.5)
0.255*
n = 23
n = 49

No. antipsychotics used, n (%)
1
2
3
4
No use
First antipsychotic of choice,
n (%)
Olanzapine
11 (47.8)
Risperidone
4 (17.4)
Quetiapine
3 (13)
Aripiprazole
3 (13)
Ziprazidone
2 (8.7)
Perphenazine
0
Haloperidol
0
Chlorpromazine
0
Amisulpride
0
Second antipsychotic of choice, n
n=6
Risperidone
1
Aripiprazole
2
Olanzapine
3
Amisulpride
0
Haloperidol
0
Ziprazidone
0
Quetiapine
0
Clozapine
0
Third antipsychotic of choice, n
n=2
Quetiapine
0
Risperidone
0
Olanzapine
0
Ziprazidone
1
Aripiprazole
1
Perphenazine
0
Levomepromazine
0
Fourth antipsychotic of choice, n
n=0
Risperidone
0
Clozapine
0

22 (44.9)
8 (16.3)
8 (16.3)
2 (4.1)
4 (8.2)
2 (4.1)
1 (2.0)
1 (2.0)
1 (2.0)
n = 19
5
5
2
2
2
1
1
1
n = 11
3
2
1
2
1
1
1
n=2
1
1

*χ2 calculated from no use, use of 1 antipsychotic, and use of more than
1 antipsychotic.
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Psychiatric Treatment
The majority of patients were in contact with the health care
system during the study period, with around two thirds in each
group having at least 1 inpatient admission at the psychiatric department. There were no significant group differences in the duration of inpatient admissions, as shown in Table 3.

DISCUSSION
A major finding in this study is the 1-year remission rate of
32% for FES patients. Results from other studies for this patient
group vary considerably. In a review of remission in schizophrenia
with 27 studies included,6 the rate of remission in FES ranged
from 17% to 78%, whereas another study showed a remission rate
of 81%.7 The variability of the reported remission rates may be a
result of the heterogeneity among the studies. Contributing factors
to the heterogeneity include selection bias and low representativeness of the studies, the definition of remission, and the frequency
and duration of follow-up. The stringent criteria used in this study,
such as a core-schizophrenia diagnosis, FES, and both dimensions
of the proposed remission criteria27 —symptom reduction and duration, are likely to have contributed to the relatively low remission
rate. However, treatment factors vary between studies and are likely
to influence remission rates. We found that all of the nonremitted
patients had at least 1 positive symptom during follow-up. These results indicate the use of antipsychotics in all of the nonremitted patients in our study, given that antipsychotics are most effective in the
treatment of positive symptoms of schizophrenia. It is possible that
these patients may have remitted, had they received a more intensified treatment with antipsychotics according to the guidelines. A
proportion of these patients should probably be evaluated for treatment with clozapine. These results also underline, however, that
even with optimal antipsychotic effect on positive symptoms, there
would be a proportion of patients still not achieving remission, because of the presence of negative symptoms.
The second major finding of our study is a low exploitation
of treatment options of antipsychotic treatment in the nonremitted
group. For this group, 7% did not use any antipsychotic drug during
the 1-year follow-up, and a further 57% were treated with one antipsychotic drug only. Contrary to the guidelines, the majority of the
nonremitted FES patients (64%) did not commence the second step
of the algorithm. Fifteen percent of the nonremitted patients received 2 antipsychotic drugs, 1 of these was prescribed clozapine,
and the others were not further switched to clozapine despite
nonremission and therefore did not pass the second step of the
guideline algorithm. Altogether, only 2 patients were offered clozapine, one as a second choice and the other as a fourth choice. In
both cases, the recommended guidelines were not followed.
The 7% nonuse together with 57% of patients receiving 1 antipsychotic drug only in a cohort of nonremitted patients with

TABLE 3. Characteristics of Admissions During First Year of
Treatment for Patients With First-Episode Core Schizophrenia,
Divided by Remission Status at 1-Year Follow-up

No. admissions, n (%)
• None
• One or more
Duration of all admissions,
mean (SD), wk

538

Remitted
(n = 25)

Nonremitted
(n = 53)

Total, n = 25
10 (40.0)
15 (60.0)
n = 25
9.66 (14.9)

Total, n = 50
14 (28.0)
36 (72.0)
n = 49
13.16 (17.4)

www.psychopharmacology.com

P
0.294

0.157

schizophrenia must be regarded as nonadherence to well-known
national and international treatment guidelines. The nonuse of
antipsychotics is a major concern. We have not explored other reasons for not taking any antipsychotic, such as patients' unwillingness, and therefore, it is not possible to conclude that the clinicians
did not follow the guidelines for schizophrenia treatment in all of
these cases. There are many factors shown to influence nonadherence to consensus-based guidelines by treating clinicians. The
applicability of clinical practice guidelines in psychiatry has been
studied during recent years, including trying to identify barriers to
guideline adherence.31–34 Some proposed barriers are physician
related, such as lack of awareness or familiarity, lack of agreement
and concerns about control over professional practice. There are
also patient-related barriers such as nonadherence and reluctance,
clarity and complexity of guidelines, and environmentally related
barriers such as resources and facilities.31,35
However, clinicians in our study performed good clinical
practice in prescribing mainly second-generation antipsychotic drugs,
and first-generation antipsychotic drugs were used in only a few
cases. For example, the United Kingdom NICE guidelines recommend treatment with at least 1 nonclozapine second-generation antipsychotic drug for treatment-resistant patients.11 The Texas
Medication Algorithm Project algorithm for schizophrenia provides
some recommendations for treatment of FES.36 In the 2003 version,
clinicians could choose either a first-generation antipsychotic drug or
clozapine after 2 inadequate trials with second-generation antipsychotics. In the 2007 update, first-generation antipsychotics
were an option at the second step of the algorithm and after a trial
of a second-generation antipsychotic at the first step. The third
step included the use of clozapine only. By contrast, the Norwegian
guidelines do not differentiate the 2 types of antipsychotic drugs in
terms of timing of treatment.15 In general, the wide use of
second-generation antipsychotic drugs by clinicians in our study
does not come in conflict with the contemporary national and international guidelines for treatment of FES.
The finding of similar rates of nonuse of antipsychotics between the remitted and the nonremitted groups may be indicative
of the heterogeneity of schizophrenia. It would be valuable to follow the course of these patients with respect to the course of illness, diagnosis, and future antipsychotic treatment. Our finding
that 2 patients remitted without using antipsychotics may challenge the general recommendation for continuous antipsychotic
treatment in the first year of FES.
Regarding clozapine treatment and its limited use, various
barriers have been investigated.37–40 Studies show that most practitioners are familiar with the guidelines and the effectiveness of
clozapine38 but are reluctant to prescribe the drug because of the
risk of fatal adverse reactions such as agranulocytosis.37,39 Lack
of knowledge of the current evidence for clozapine may be contributing to this finding because very few patients on clozapine
progress from neutropenia to agranulocytosis,41 and other antipsychotics also pose a risk of agranulocytosis.42 This small risk
of agranulocytosis is, in our opinion, outweighed by a reduced
mortality associated with clozapine treatment.43
For the proportion of nonremitted patients with at least 2
antipsychotics trials (19/53), several reasons could explain the
possible low use of clozapine. First, we are not sure if this sample
can be regarded as treatment resistant because we did not explore
if the previous treatment periods were of adequate duration and if
the antipsychotics were given in adequate doses. This is crucial to
define treatment resistance, and clozapine is only recommended
once treatment resistance is demonstrated. Second, patients may
have been offered but refused the suggested treatment because
of the comprehensive blood-monitoring associated with clozapine
use, or refused for other reasons. Third, medical contraindications
© 2020 The Author(s). Published by Wolters Kluwer Health, Inc.
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for the use of clozapine may apply. However, we found no written
evaluation of indications of clozapine in the medical files.
Adherence to guidelines could be enhanced through regular
training sessions for physicians on the implementation of the
guidelines and including information on the current evidence base
for the management of treatment with clozapine. Concerns by patients about clozapine could be addressed by providing them with
information on the advantages of clozapine and the adoption of
shared decision-making methods by clinicians. In addition, the facilities and infrastructure of the psychiatric institutions should be
improved to allow an easier and more user-friendly follow-up
for those receiving clozapine but also other antipsychotic drugs.
Some clozapine clinics have been established, and it is possible
that these facilities increase the quality of antipsychotic treatment
and the remission rate in schizophrenia.44
Future research is needed on how to optimize implementation
of evidence-based guidelines for the treatment of schizophrenia in
the early stages because this may be imperative for improving outcome for these patients.

Strengths and Limitations
The strengths of our study include a robust design, whereby
all the consecutive FES patients in a catchment area were assessed
and followed up for 1 year. The study had access to the medical
files of all patients and thus information on treatment over the
1-year follow-up. The stringent inclusion criteria ensured homogeneity in terms of diagnosis. Our study, however, was limited
by the lack of assessment of the attitudes or behavior of patients
toward treatment by medication. We are unable to determine
whether nonadherence to guidelines is underpinned by patients refusing to receive antipsychotics including clozapine. Second, the
attitudes of clinicians toward clozapine were not explored in our
study. Given the lack of written considerations of clozapine use
in the medical files, we cannot exclude that clinicians may have
considered clozapine and refused prescribing for acceptable medical reasons.

CONCLUSIONS
Our study is one of the first to examine the adherence to
guidelines for the pharmacological treatment and the 1-year remission rate for FES patients using stringent criteria. The quality
of care given to patients is often correlated to the degree to which
the clinicians follow the guidelines.45 Guidelines suggest a clinical
practice that influences good patient outcomes. Therefore, adherence to guidelines is crucial for providing effective and
evidence-based treatment. Given the finding of low adherence
to the guidelines and insufficient pharmacological treatment
for the FES patients in our study, a more evidence-based practice could be achieved by increasing guideline awareness and
training in their implementation among the clinicians.
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